In Vitro and In Vivo Testing of 177Lu-DOTA-Nimotuzumab, a Potential Radioimmunotherapeutical Agent of Cancers

Ramli, Martalena; Hidayat, Basuki; Rustendi, Cecep Taufik; Subur, Muhammad; Ardiyatno, C. N.; Karyadi, Karyadi; Aguswarini, Sri; Humani, Titis Sekar; Ritawidya, Rien; Mutalib, Abdul; Masjhur, Johan S.

doi:10.5614/itbj.sci.2012.44.4.4

Cited by 8 publications

(10 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These systems were a) Whatman Paper No.1 as stationary phase and 75% methanol as a mobile phase (Whatman No.1/75% methanol); b) ITLC-SG as stationary phase and 85% methanol as a mobile phase (ITLC-SG/85% methanol) 7 ; c) ITLC-SG as stationary phase and 100% acetone as a mobile phase (ITLC-SG/100% acetone) 5 ; and d) ITLC-SG as stationary phase and saline as a mobile phase; (ITLC-SG/saline ). 9 In this testing, free 131 I in the form of Na 131 I or the purified 131 I-Rituximab was spotted on a test strip, 1 cm from the bottom of each strip. Each strip was then developed in each representative mobile phase up to 1 cm from the top of the strip.…”

Section: This Work Was Conducted At Thementioning

confidence: 99%

“…Fractions, which contained protein and has relatively high radioactivity, underwent radiochemical purity test. 9 There were 3 procedures for radiolabeling Rituximab with 131 I that were validated in this project. These procedures involved the use of three different oxidizing agents;Iodobeads, Iodogen, and Chloramine-T. Validation of radiolabeling procedure was performed at least five times for each procedure.…”

Section: This Work Was Conducted At Thementioning

confidence: 99%

“…Purification of 131 I-Rituximab was performed by passing the raw product through a Sephadex G 25M column (10x0.8 cm AE) which had been treated with 2 mL of 10% BSA. 9 Radiolabeling for Rituximab Radiolabeling with 131 I using Iodogen as theoxidizing agent, Rituximab aliquot (5 mg in 500 mL) was added to an Iodogen coated tube. The Iodogen coated tube was prepared by adding Iodogen aliquot (1 mg/mL in CHCl 3 ) into a clean tube, followed by evaporating the solvent to dryness using N 2 .…”

Section: This Work Was Conducted At Thementioning

confidence: 99%

See 2 more Smart Citations

Rituximab Iodination Procedure for Radioiodinated Rituximab (131I-Rituximab) Preparation

Ramli¹,

Hidayat²,

Sutari³

et al. 2019

mkb

Self Cite

View full text Add to dashboard Cite

Rituximab is a chimeric monoclonal antibody which has specific for CD20 antigen expressed by pre-B and mature B-cells. Radiolabelled Rituximab, 131 I-Rituximab, has been sucessfully used for treatment of B-Cell NHL. Due to its short shelf-life, 131 I-Rituximab is commonly freshly prepared in hospitals prior to its used. This study aimed to validate rituximab iodination procedure for 131I-Rituximab preparation in order to find the most suitable procedure to be applied in hospitals which intend to produce 131 I-Rituximab in-house. Three different methods of radiolabelling using three types of oxidizing agents, namely Iodobeads, Iodogen, and Chloramine-T were performed. Prior to the validation, radiochemical purity test and purification procedures were also validated as these procedures are critical for producing an acceptable quality of I-Rituximab. In addition, the shelf-life of 131 I-Rituximab was also studied. This study was conducted at the Centre for Radioisotope and Radiopharmaceutical Technology, Serpong during the period of July 2015 to February 2018. The results showed that the radiochemical purity test of 131 I-Rituximab could be easily performed by using instance thin layer chromatography-silica gel (ITLC-SG) in the stationary phase and 85% methanol or saline in the mobile phase. Purification of 131 I-Rituximab was conducted using a Sephadex G-25 M filled column with 0.1 M PBS, pH 7.2, as the eluent that was found to be quite reliable to give 131 I-Rituximab with radiochemical purity of >95% and recovery of approximately 90%. Radiolabelling efficiency performed using Iodobeads was the lowest (60%) compared to that of Iodogen and Chloramine-T (80-90%). In addition, approximately 30% of I was retained by Iodobeads and this procedure was time consuming(~1 hours). It is concluded that Chloramine-T and Iodogen are better than Iodobeads as the oxidizing agent for radiolabelling of Rituximab with 131 I. The radiochemical purity of 131 I-Rituximab is well maintained when stored at room temperature and in 4 °C temperature up to 6 hours.

show abstract

Section: This Work Was Conducted At Thementioning

confidence: 99%

Section: This Work Was Conducted At Thementioning

confidence: 99%

Section: This Work Was Conducted At Thementioning

confidence: 99%

See 1 more Smart Citation

Rituximab Iodination Procedure for Radioiodinated Rituximab (131I-Rituximab) Preparation

Ramli¹,

Hidayat²,

Sutari³

et al. 2019

mkb

Self Cite

View full text Add to dashboard Cite

show abstract

“…Dalam perkembangan terakhir, nimotuzumab telah terfragmentasi dan kemudian dapat diberi label menggunakan diagnostik dan terapeutik radionuklida, seperti gallium-68, yttrium-90, lutetium-177, dan holmium-166. Sitotoksisitas 177 Lu-DOTA-Nimotuzumab dapat membunuh sel line A549 (karsinoma paru) lebih baik dibanding nimotuzumab tanpa tracer (penanda) (Ramli et al, 2012).…”

Section: Pendahuluanunclassified

“…Campuran kemudian diinkubasi kembali selama 3 jam pada suhu 2-8 o C terlindung dari cahaya. Prosedur yang sama juga digunakan untuk penyiapan AuNP-PAMAM G4 dengan Nimotuzumab (Ramli et al, 2012).…”

Section: Konjugasi Nimotuzumab Pada 198 Aunp-pamam G4unclassified

Clearance profile of radioactive gold nanoparticle (198Au) conjugates-poliamidoamin generation 4-nimotuzumab ; potential radio-pharmaceutical theranostic agent

Halid

Mutalib

Pujiyanto³

et al. 2017

Pharmaciana

Self Cite

View full text Add to dashboard Cite

Agen theranostic merupakan agen yang berfungsi menggabungkan kemampuan diagnostik dan terapeutik menjadi agen tunggal. Adanya konjugasi agen terapi kanker seperti antibodi monoklonal nimotuzumab dengan nanopartikel emas radioaktif yang distabilisasi dengan dendrimer poliamidoamin generasi 4 (PAMAM G4) dapat secara aktif berinteraksi spesifik dengan sel kanker. Emas radioaktif (198 Au) sebagai pemancar radiasi β (961 keV) yang mampu membunuh sel kanker dan sinar γ (412 keV) yang memberikan citra emas dalam tubuh, sehingga dapat berperan sebagai suatu agen theranostic. Tujuan dari penelitian ini untuk memperoleh hasil yang meyakinkan keamanan konjugat dengan mengamati klirens konjugat 198 AuNP-PAMAM G4-Nimotuzumab. Hasil klirens konjugat akan menjadi acuan keadaan metabolisme sebagai radiofarmaka baru yang stabil dan utuh pada saat sampai di target yang diinginkan. Penelitian ini dimulai dengan sintesis konjugat 198 AuNp-PAMAM G4-nimotuzumab dan kemudian dilakukan uji klirens serta analisa hasil urin dan feses tikus yang telah diinjeksikan konjugat. Total klirens yang diperoleh sekitar 47,38 % dari konjugat 198 AuNP-PAMAM G4-Nimotuzumab yang telah diekskresikan melalui urin (18,26 %) dan feses (29,11 %.). Urin dan feses tersebut dianalisa dengan SDS-PAGE memberikan yang memberikan spot diatas pita 150 kDa dan menunjukkan berat molekul konjugat. Analisis FTIR urin dan feses dengan menunjukkan gugus fungsi aldehid (C=O), gugus alkohol (O-H), gugus amina (C-N), serta gugus amina (N-H) yang menandakan adanya konjugat AuNP-PAMAM G4-Nimotuzumab dalam urin maupun feses tikus. Hasil eksresi urin dan feses dari konjugat dianggap masih berbentuk konjugat didukung dengan analisis SDS PAGE, analisis serapan spektrofotometer UV-Vis dan analisis gugus fungsi dengan FTIR yang dilakukan.

show abstract

Implementation of dosimetry protocol for radionuclide therapy in Indonesia: Collaborative works in nuclear medicine

Hidayati¹,

Mailana²,

Widodo³

et al. 2021

PROCEEDINGS OF THE INTERNATIONAL CONFERENCE AND SCHOOL ON PHYSICS IN MEDICINE AND BIOSYSTEM (ICSPMB): Physics Contribution in M

View full text Add to dashboard Cite

In Vitro and In Vivo Testing of 177Lu-DOTA-Nimotuzumab, a Potential Radioimmunotherapeutical Agent of Cancers

Cited by 8 publications

References 3 publications

Rituximab Iodination Procedure for Radioiodinated Rituximab (131I-Rituximab) Preparation

Rituximab Iodination Procedure for Radioiodinated Rituximab (131I-Rituximab) Preparation

Clearance profile of radioactive gold nanoparticle (198Au) conjugates-poliamidoamin generation 4-nimotuzumab ; potential radio-pharmaceutical theranostic agent

Implementation of dosimetry protocol for radionuclide therapy in Indonesia: Collaborative works in nuclear medicine

Contact Info

Product

Resources

About